Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagihara, Katsunobu, Chan, Stephen, Zhang, Li, Oh, David Y., Wei, Xiao X., Simko, Jeffry, Fong, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287789/
https://www.ncbi.nlm.nih.gov/pubmed/30546940
http://dx.doi.org/10.1080/2162402X.2018.1486953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287789/
https://www.ncbi.nlm.nih.gov/pubmed/30546940
http://dx.doi.org/10.1080/2162402X.2018.1486953

Ejemplares similares